Vaxart received another stop work order for its federally funded oral Covid-19 vaccine Phase 2b trial managed by Advanced Technology International, halting most trial activities despite ongoing participant follow-up. The trial, involving 10,000 subjects, had previously experienced a suspension and reinstatement of work under the contract. Vaxart’s CEO highlighted the absence of explicit reasons for the stoppage as the US Department of Health and Human Services winds down mRNA vaccine development programs. The development reflects evolving federal support dynamics in vaccine research funding.